Loading clinical trials...
Loading clinical trials...
Brain Function and Psychological Assessment in Patients With Autoimmune Hemolytic Anemia Undergoing Cell Therapy
Cell therapy is an innovative treatment with significant efficacy in hematologic and certain autoimmune diseases. Although it offers potential benefits for autoimmune hemolytic anemia (AIHA), it may result in cognitive and other potential impairments, which can adversely affect patients' cognition and behavior. Brain function and psychological assessment are essential for the early detection of potential impairments, allowing timely interventions to prevent complications and ensure patient safety. This study aims to comprehensively evaluate the physical and psychological impacts of cell therapy on AIHA patients to develop safer and more effective treatment strategies that enhance their quality of life.
Age
18 - 65 years
Sex
ALL
Healthy Volunteers
No
Regenerative Medicine Center
Tianjin, Tianjin Municipality, China
Start Date
February 25, 2025
Primary Completion Date
December 31, 2026
Completion Date
December 31, 2026
Last Updated
August 5, 2025
20
ESTIMATED participants
Brain function and psychological assessment
OTHER
Lead Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Collaborators
NCT04645199
NCT07361094
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions